{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016454","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.496257+00:00","generated_at":"2026-06-24T01:26:45.959343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025","bullets":["Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.","Cash and securities $223.6M as of June 30, extended cash runway through 2025 via portfolio prioritization.","BDC-1001 monotherapy/combination dose-escalation data and RP2D expected H2 2022.","BDC-2034 discontinued due to off-target toxicity; focus on BDC-1001, BDC-3042, and next-gen ISAC.","BDC-3042 IND-enabling studies underway; clinical start on track for 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016454","json":"https://secwatch.observer/filing/0000950170-22-016454.json","markdown":"https://secwatch.observer/filing/0000950170-22-016454.md","text":"https://secwatch.observer/filing/0000950170-22-016454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/0000950170-22-016454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/bolt-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:26:45.959343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}